Rituximab: all 1,386 studies that test it
Page 8 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSLStatus unknownNCT05425654Phase 2
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)Active, not recruitingNCT05406401Phase 2
- R-MTX-zanbrutinib in Secondary CNS LymphomaStatus unknownNCT05398224Phase 2
- Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialStatus unknownNCT05392257Phase 2
- A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaCompletedNCT05364424Phase 1
- Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia GravisStatus unknownNCT05332587Phase 3
- Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA VasculitisCompletedNCT05329090Phase 3
- Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic DisordersWithdrawnNCT05293509Phase 2
- Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
- A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHLTerminatedNCT05265975Phase 1/2
- Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLLWithdrawnNCT05209308Phase 2
- A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
- Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid StudyStatus unknownNCT05191225Phase 4
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Phase 3
- Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple SclerosisStatus unknownNCT05078177Phase 1
- Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus ErythematosusStatus unknownNCT05057481Phase 3
- Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
- A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSLCompletedNCT05036577Phase 1
- ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT05025800Phase 1/2
- Acalabrutinib and Rituximab in Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT05004064Phase 2
- Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop StudyActive, not recruitingNCT04978584Phase 2
- A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)WithdrawnNCT04974996Phase 1
- Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or OlderActive, not recruitingNCT04974216Phase 2
- Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT04934579Phase 2
- Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRLStatus unknownNCT04899453Phase 2
- Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaWithdrawnNCT04882163Phase 1/2
- Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaActive, not recruitingNCT04872790Phase 1
- A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT04790903Phase 1
- Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic SyndromeCompletedNCT04783675Phase 2
- Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe HemoglobinopathiesWithdrawnNCT04776850Early Phase 1
- Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04765111Phase 2
- A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaActive, not recruitingNCT04712097Phase 3
- Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisActive, not recruitingNCT04688788Phase 3
- Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.CompletedNCT04688151Phase 1
- Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's MacroglobulinemiaActive, not recruitingNCT04624906Phase 2
- Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS LymphomaActive, not recruitingNCT04609046Phase 1
- A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCLActive, not recruitingNCT04594798Phase 2
- Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaStatus unknownNCT04588194Phase 2
- Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.Status unknownNCT04585152Phase 2
- Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseActive, not recruitingNCT04578639Phase 3
- Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in ChildrenStatus unknownNCT04542629Phase 4
- Rituximab and RASi in Patients with IgANCompletedNCT04525729Phase 4
- Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot TrialStatus unknownNCT04507477Phase 1/2
- Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT04502706Phase 1
- Rituximab for Idiopathic Nephrotic SyndromeCompletedNCT04494438Phase 3
- Rituximab in Chronic Inflammatory Demyelinating PolyneuropathyWithdrawnNCT04480450Phase 2
- Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaActive, not recruitingNCT04479267Phase 2
- Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
- Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT04458610Phase 2
- An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentActive, not recruitingNCT04447716Phase 1
- VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedNCT04433156Phase 2
- Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1
- A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaActive, not recruitingNCT04416451Phase 2
- Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic SyndromeTerminatedNCT04402580Phase 2
- Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT04361409Phase 1
- A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCLCompletedNCT04361279Phase 3
- Rituximab Combined With Chidamide and Lenalidomide for r/r AITLStatus unknownNCT04319601Not applicable
- Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT04285268Phase 2
- A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCLWithdrawnNCT04279938Phase 1
- Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE)CompletedNCT04256252Phase 4
- Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell LymphomaStatus unknownNCT04246359Phase 2
- FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesTerminatedNCT04245722Phase 1
- CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in ChildrenCompletedNCT04224571Phase 2
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Phase 3
- A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaActive, not recruitingNCT04212013Phase 3
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT04161248Early Phase 1
- Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular LymphomaTerminatedNCT04156828Phase 1
- NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaCompletedNCT04136756Phase 1
- Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)CompletedNCT04121403Phase 3
- Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic AnemiaCompletedNCT04083014Phase 2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
- Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCLCompletedNCT04022005Phase 2
- Rituximab for HTLV-1-associated MyelopathyStatus unknownNCT04004819Phase 2
- Transplant Antibody-Mediated Rejection: Guiding Effective TreatmentsTerminatedNCT03994783Phase 3
- Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)CompletedNCT03983031Phase 1
- RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MSActive, not recruitingNCT03979456Phase 3
- RItuximab From the FIRst Episode of Idiopathic Nephrotic SyndromeStatus unknownNCT03970577Phase 2
- Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
- Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and LymphomaCompletedNCT03934814Phase 1
- Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic PolyangiitisCompletedNCT03920722Phase 3
- Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat LymphomaCompletedNCT03900377Phase 1/2
- A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's SyndromeActive, not recruitingNCT03899337Phase 2
- Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT03892421Phase 1/2
- The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 AutoantibodiesCompletedNCT03864185Phase 2
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic SclerosisActive, not recruitingNCT03844061Phase 2
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
- Autologous Transplant To End NMO Spectrum DisorderWithdrawnNCT03829566Phase 2/3
- The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
- Personalized Medicine for Membranous NephropathyCompletedNCT03804359Phase 2
- Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCLStatus unknownNCT03795571Phase 1
- Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" TrialCompletedNCT03790293Phase 3
- A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic CancersTerminatedNCT03783403Phase 1
- MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell OriginStatus unknownNCT03778619Phase 1/2
- Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03777085Phase 3
- PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantCompletedNCT03763643Early Phase 1
- Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)CompletedNCT03703167Phase 1
- Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia AStatus unknownNCT03700229Phase 2
- MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone LymphomasActive, not recruitingNCT03697512Phase 2
- Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin LymphomaStatus unknownNCT03688451Phase 2
- A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03670901Phase 3